ESTRO 2024 - Abstract Book

S5056

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2024

Figure 1. Plot of the 2 year overall survival univariable model by retreatment dose. The blue line is the fitted regression model, black dotted lines represent the standard error of the regression, the red dotted line indicates the 50% 2-year overall survival rate. The dots represent the toxicity rate from each individual paper coded by colour, with the size of the dots proportional to the number of patients in the study, vertical bars are the 68% binomial confidence interval.

Conclusion:

We developed a NSCLC re-irradiation dose/tumour control probability model based on the re-treatment dose. This model was well correlated with the data the model was derived from (Pearson correlation coefficient >0.7) with a relatively narrow bootstrapped 95% CI. In clinical practice, a retreatment dose of 76.5 EQD2 Gy may be difficult to achieve while also meeting suggested re-irradiation dose constraints using conventional fractionation. Highly conformal treatment e.g. SABR or ion therapy may therefore be an attractive option for recurrent NSCLC.

Keywords: Re-irradiation, lung cancer, tumour control

References: